Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04848844

The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)

Advances in surgical and medical care have led to improved outcomes in patients with congenital heart disease (CHD). As a consequence, the majority of patients nowadays survives to adulthood (adults with CHD, that is, adult CHD [ACHD]) with good quality of life. Despite the surgical success, the morbidity and mortality of ACHD is higher than in the general population and is linked to the development of heart failure (HF) in adulthood.

HF occurs in approximately 25% of patients with ACHD, even in those patients in whom the congenital mal-formation has been corrected successfully in childhood. The time course and presentation are heterogeneous owing to variable congenital malformation and limitation of treatment options. ACHD with an anatomic right ventricle as the systemic ventricle (e.g., atrial switch operation in patients with transposition of the great arteries [TGAs]) and those with a functional single ventricle (e.g., Fontan circulation) appear to be at higher risk of developing HF. Young age at initial corrective surgery-often in the first 2 years of life-and lack of specific medical therapies can contribute to a high and early demand for heart transplantation in patients with ACHD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Heart and Vascular Center Hamburg

Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

Location status: Recruiting

Location contact

Christina Magnussen, MD

CONTACT

[email protected]

Christoph Sinning, MD

CONTACT

[email protected]

004915222817675

About this study

The ARTORIA-R is an international, observational research project collecting retrospective data from 18 countries in the period 1989 to 2024 and will thereafter include data prospectively (Figure 1). These data include patient profiles at time of evaluation for listing, listing, waiting list dynamics, post-transplant data and basic donor data. Future data will be updated annually in July each year and each institution willing to contribute anonymised data to the register is invited to participate. Furthermore, the institutions and organ allocation agencies have to obtain a positive vote of the ethic committee responsible for the data transmission of anonymized patient data.

The inclusion criteria are: a. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years b. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD c. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation d. Transfer of anonymised data e. The institution/organization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions. The registry has the aim to achieve meticulous information regarding the underlying congenital heart defect and the previous treatment of the patient. With these information the patients can be divided into different cohorts with a systemic left ventricle, a systemic right ventricle or a single ventricle (which can be either an anatomic left or right ventricle). Further data is acquired regarding the medical treatment, the haemodynamic evaluation of the patient, laboratory testing to assess additional organ function of the kidney or liver, treatment in the intermediate care or intensive care unit. As it is of special relevance in ACHD patient treatment of arrhythmia, antiarrhythmic medication and use of ICD or cardiac resynchronization therapy are evaluated. Were available the data regarding imaging at listing with ejection fraction for the systemic ventricle with echocardiography or cardiac magnetic resonance imaging are obtained.

The exclusion criteria is: a. The patient is listed for a second heart transplantation (retransplantation) During the ongoing study additional institutions and organizations will be asked to include their data as well. Although the initial data is retrospective additional data into the register will be entered prospectively.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years
  • The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD
  • Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation
  • Transfer of anonymised data
  • The institution/organization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions

Exclusion criteria

a. The patient is listed for a second heart transplantation (retransplantation)

Treatment and study plan

Primary outcomes

  1. Delisting due to clinical worsening or death on the waiting list

    Time frame: From the date of listing until delisting due to clinical worsening, death on the waiting list, transplantation, or last available follow-up, assessed up to 15 years.

    Patients who experience clinical worsening due to advanced heart failure may be removed from the waiting list. Patients may also die while on the waiting list.

Secondary outcomes

  1. Delisting due to clinical improvement

    Time frame: From the date of listing until the date of delisting due to clinical improvement, transplantation, death, or last available follow-up, whichever occurs first, assessed up to 15 years.

    Patients may improve after listing and be removed from the waiting list because they no longer fulfill the criteria for heart or combined organ transplantation.

Other outcomes

  1. All-cause mortality following transplantation

    Time frame: From the date of transplantation until the date of death from any cause or last available follow-up, whichever occurs first, assessed up to 15 years after transplantation.

    Patients who undergo successful transplantation are followed at the transplant center, and vital status is recorded during follow-up.

  2. Implantation of a ventricular assist device as a bridge to transplantation, bridge to candidacy, or destination therapy

    Time frame: From the date of registry inclusion until the date of ventricular assist device implantation or last available follow-up, whichever occurs first, assessed up to 15 years.

    Some patients will receive a ventricular assist device as a bridge to transplantation or candidacy; others may receive the device as destination therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

Christina Magnussen, MD

CONTACT

[email protected]

Christoph Sinning, MD

CONTACT

[email protected]

004915222817675

Sponsors and collaborators

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Other

Collaborators

  • Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Registry information

Official study title

The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart/Lung Transplantation

Acronym: ARTORIA-R

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Apr 19, 2021
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.